REGENXBIO Inc. Earnings Per Share (Basic)
REGENXBIO Inc. (RGNX) reported Earnings Per Share (Basic) of $0.43 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- REGENXBIO Inc. earnings per share, basic for the quarter ending 2026-06-30 was $0.43.
- REGENXBIO Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$1.72, a 1533.33% decline year-over-year.
- REGENXBIO Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$1.20.
- REGENXBIO Inc. earnings per share, basic for the quarter ending 2025-06-30 was -$1.38.
- REGENXBIO Inc. earnings per share, basic for fiscal 2025 was -$3.76.
- REGENXBIO Inc. earnings per share, basic for fiscal 2024 was -$4.59.
- REGENXBIO Inc. earnings per share, basic for fiscal 2023 was -$6.02.
- REGENXBIO Inc. earnings per share, basic for fiscal 2022 was -$6.50, a 315.95% decline from fiscal 2021.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.43 10-Q · filed 2026-08-06 | -$1.28 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | -$1.72 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | -$3.76 10-K · filed 2026-03-05 | |||
| 2025-09-30 | -$1.20 10-Q · filed 2025-11-06 | -$2.46 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | -$1.38 10-Q · filed 2026-08-06 | -$1.26 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $0.12 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | -$4.59 10-K · filed 2026-03-05 | |||
| 2024-09-30 | -$1.17 10-Q · filed 2025-11-06 | -$3.59 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | -$1.05 10-Q · filed 2025-08-07 | -$2.41 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$1.38 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$6.02 10-K · filed 2025-03-13 | |||
| 2023-09-30 | -$1.41 10-Q · filed 2024-11-06 | -$4.60 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | -$1.66 10-Q · filed 2024-08-01 | -$3.19 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | -$1.53 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$6.50 10-K · filed 2025-03-13 | |||
| 2022-09-30 | -$1.75 10-Q · filed 2023-11-08 | -$5.11 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | -$1.58 10-Q · filed 2023-08-02 | -$3.37 10-Q · filed 2023-08-02 | ||
| 2022-03-31 | -$1.79 10-Q · filed 2023-05-03 | |||
| 2021-12-31 | $1.73 derived: net income ÷ weighted average shares · filed 2024-02-27 | $2.78 derived: net income ÷ weighted average shares · filed 2024-02-27 | $3.01 10-K · filed 2024-02-27 | |
| 2021-09-30 | -$1.37 10-Q · filed 2022-11-03 | -$3.93 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | -$1.36 10-Q · filed 2022-08-03 | -$2.56 10-Q · filed 2022-08-03 | ||
| 2020-12-31 | -$1.24 10-K · filed 2021-03-01 | -$1.00 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.98 10-K · filed 2023-02-28 | |
| 2020-09-30 | $0.24 10-Q · filed 2021-11-02 | -$1.75 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | -$0.91 10-K · filed 2021-03-01 | |||
| 2020-03-31 | -$1.08 10-K · filed 2021-03-01 | |||
| 2019-12-31 | -$0.72 10-K · filed 2021-03-01 | -$1.66 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$1.70 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$2.58 10-K · filed 2022-03-01 |
| 2019-09-30 | -$0.94 10-K · filed 2021-03-01 | -$0.98 derived: net income ÷ weighted average shares · filed 2020-11-04 | -$1.86 10-Q · filed 2020-11-04 | -$1.75 derived: net income ÷ weighted average shares · filed 2021-03-01 |
| 2019-06-30 | -$0.04 10-K · filed 2021-03-01 | -$0.92 10-Q · filed 2019-08-07 | -$0.81 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$1.36 derived: net income ÷ weighted average shares · filed 2021-03-01 |
| 2019-03-31 | -$0.89 10-K · filed 2021-03-01 | -$0.77 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$1.33 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$1.06 derived: net income ÷ weighted average shares · filed 2021-03-01 |
| 2018-12-31 | $0.12 10-K · filed 2020-02-26 | -$0.43 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$0.13 derived: net income ÷ weighted average shares · filed 2021-03-01 | $2.99 10-K · filed 2021-03-01 |
| 2018-09-30 | -$0.56 10-K · filed 2020-02-26 | -$0.26 derived: net income ÷ weighted average shares · filed 2019-11-05 | $2.94 10-Q · filed 2019-11-05 | $2.47 derived: net income ÷ weighted average shares · filed 2020-02-26 |
| 2018-06-30 | $0.33 10-K · filed 2020-02-26 | $3.60 10-Q · filed 2019-08-07 | $3.12 derived: net income ÷ weighted average shares · filed 2020-02-26 | $2.48 derived: net income ÷ weighted average shares · filed 2020-02-26 |
| 2018-03-31 | $3.30 10-K · filed 2020-02-26 | $2.81 derived: net income ÷ weighted average shares · filed 2020-02-26 | $2.16 derived: net income ÷ weighted average shares · filed 2020-02-26 | $1.71 derived: net income ÷ weighted average shares · filed 2020-02-26 |
| 2017-12-31 | -$0.51 10-K · filed 2019-02-27 | -$1.18 derived: net income ÷ weighted average shares · filed 2020-02-26 | -$1.65 derived: net income ÷ weighted average shares · filed 2020-02-26 | -$2.45 10-K · filed 2020-02-26 |
| 2017-09-30 | -$0.67 10-K · filed 2019-02-27 | -$1.14 derived: net income ÷ weighted average shares · filed 2018-11-07 | -$1.94 10-Q · filed 2018-11-07 | |
| 2017-06-30 | -$0.47 10-K · filed 2019-02-27 | -$1.27 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | -$0.82 10-K · filed 2019-02-27 | |||
| 2016-12-31 | -$2.38 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |